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The objective of this review was to compare and contrast the physiological and meta-
bolic profiles of rodent white adipose fat pads with white adipose fat depots in humans. 
Human fat distribution and its metabolic consequences have received extensive 
attention, but much of what has been tested in translational research has relied heavily 
on rodents. Unfortunately, the validity of using rodent fat pads as a model of human 
adiposity has received less attention. There is a surprisingly lack of studies demonstrat-
ing an analogous relationship between rodent and human adiposity on obesity-related 
comorbidities. Therefore, we aimed to compare known similarities and disparities in 
terms of white adipose tissue (WAT) development and distribution, sexual dimorphism, 
weight loss, adipokine secretion, and aging. While the literature supports the notion 
that many similarities exist between rodents and humans, notable differences emerge 
related to fat deposition and function of WAT. Thus, further research is warranted to more 
carefully define the strengths and limitations of rodent WAT as a model for humans, with 
a particular emphasis on comparable fat depots, such as mesenteric fat.
Keywords: rodents, humans, obesity, fat pads, fat depot, fat distribution
iNTRODUCTiON
Obesity has largely been defined by a body mass index (BMI) >30 kg/m2, or better still, a body fat 
percentage >25% in males and >35% in females (1). However, from a physiological standpoint, 
evidence indicates that body fat distribution, irrespective of BMI and/or body fat percentage, most 
strongly predicts risk of obesity-related diseases and complications (2). Risk can further be stratified 
by fat distribution, as individuals with a higher waist-to-hip ratio suffer disproportionately from 
obesity-related metabolic dysfunction (3). Indeed, individuals with gynoid obesity, characterized by 
subcutaneous fat in the gluteofemoral region, have minimal risk of developing metabolic dysfunc-
tion (3, 4); whereas individuals with the so-called android obesity, which is characterized by visceral 
fat accretion, suffer a greater risk of metabolic dysfunction (4, 5).
Abbreviations: BMI, body mass index; CR, caloric restriction; DSAT, deep subcutaneous adipose tissue; HOX, homeobox; 
IL-6, interleukin-6; SAT, subcutaneous adipose tissue; SSAT, superficial subcutaneous adipose tissue; TNF-α, tumor necrosis 
factor-α; VAT, visceral adipose tissue.
FiGURe 1 | (A) Distribution of fat depots in the human. The white adipose tissue (WAT) is found in subcutaneous adipose tissue (SAT) abdominally (a), 
gluteofemorally (g), and intramuscularly (h). WAT is also found in the visceral adipose tissue (VAT). The visceral depots are omental (b), mesenteric (c), retroperitoneal 
(d), gonadal (e), and pericardial (f). Brown adipose tissue is found supraclavicularly (i) and in the subscapular region (j). (B) Those fat depots linked to increased risk of 
developing obesity-related morbidities and mortality are colored in red (13).
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The metabolic consequences of body fat and its distribution 
have received extensive attention in the literature. As rodents 
are by far the most commonly used pre-clinical model of human 
obesity (6–9), further validation of important commonalities and 
differences between rodent and humans are needed. Specifically, 
investigators should seriously consider to what extent their 
experimental approach and findings are translational. For 
instance, rodent adipose tissue deposition is strikingly dissimilar 
to humans, and adipocytes in these depots display metabolic 
heterogeneity and are intrinsically different within a species. 
As such, further research needs to focus on how specific rodent 
fat pads correspond, if at all, with fat depots in humans. To our 
knowledge, only two studies have compared gene expression in 
mouse fat pads to gene expression in analogous human fat depots 
(10, 11). Thus, given the general lack of information or discussion 
on this highly relevant topic, a systemic review of the literature in 
our view, is warranted.
FAT DePOTS veRSUS FAT PADS: 
ANATOMiCAL CONSiDeRATiONS
There are three main regional human anatomical fat depots: 
intra-abdominal, upper-body/abdominal subcutaneous, and 
lower body subcutaneous (Figure  1A) (12). Intra-abdominal 
refers to visceral adipose tissue (VAT), which surrounds the inner 
organs (13). VAT can further be divided into omental, mesen-
teric, retroperitoneal, gonadal, and pericardial. The upper-body 
subcutaneous adipose tissue (SAT) can be categorized depending 
on if it is situated superficial or deep to the fascia superficialis. 
The adipose tissue below the fascia is the deep subcutaneous 
adipose tissue (DSAT) compartment, whereas adipose tissue 
located superficially to this fascia is the superficial subcutaneous 
adipose tissue (SSAT) compartment (14, 15). Though SAT is 
distributed throughout the human body, the main depots are in 
the abdomen, buttocks, and thighs (16). The buttocks and thighs 
make up the lower body SAT and are termed the gluteofemoral 
depot (12, 13).
Like humans, adipose tissue in rodents is a multi-depot organ 
(Figure 2), but unlike humans, which have two main subcutane-
ous depots located in the abdominal and gluteofemoral region, 
rodents have two main subcutaneous pads located anteriorly and 
posteriorly. The anterior pad is located between the scapulae, 
descending from the neck to the axillae (17), while, the posterior 
pad, or inguinal fat pad, spreads from the dorsolumbar region to 
the gluteal region. The inguinal fat pad is comparable in terms 
of location to the large gluteofemoral subcutaneous depot in 
humans. Additionally, rodent SAT is separated from dermal 
adipose tissue by a smooth muscle layer, whereas, in humans, the 
SAT is continuous with dermal adipose tissue (17). Furthermore, 
there has been no evidence to our knowledge of multiple subcu-
taneous layers in rodents, such as is the case in humans.
Rodents harbor visceral fat pads in the perigonadal region, 
known as epididymal in males and periovarian in females, as well 
as retroperitoneal fat pads located on the kidneys, and the mesen-
teric fat pad located alongside the intestinal tract. The mesenteric 
fat pad is widely touted as the most analogous to human intra-
abdominal adipose tissue both in its location and biology, because 
it has access to the portal vein. However, this depot is not well 
studied in rodents due to limitations in its surgical manipulation 
FiGURe 2 | Distribution of fat pads in the mouse. The fat is composed of two subcutaneous pads and several visceral pads. The main white adipose tissue 
(WAT) pads are the inguinal and epididymal, with the latter being the most frequent dissected pad. Brown adipose tissue (BAT) is distributed throughout the fat pads 
with the main BAT depot in the interscapular region (18).
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and separation from contaminating vessels. The perigonadal fat 
pads are typically the largest and most readily accessible fat pads 
and, for these and other reasons, they are the most frequently 
used in the literature (19–21). However, humans do not harbor a 
fat depot analogous to these fat pads, which has led to the sugges-
tion that these pads should be considered “peri-visceral” rather 
than true visceral fat pads. Another difference between the two 
species is the ambiguity when referencing the omental depot in 
rodents. Though it is clearly defined and developed in humans, it 
is less so in rodents, leading some investigators to not reference 
the omental depot at all (13). However, based on the literature, it 
seems that the omental depot is present in the mouse, albeit in 
small quantities, and is similarly connected to the stomach, as it 
is in humans (22). Thus, although adipose tissue is a multi-depot 
organ in both humans and rodents, there are anatomical differ-
ences that should be taken into consideration.
FAT PAD AND DePOT DiSTRiBUTiON iN 
HeALTH AND DiSeASe
In humans, increased VAT is associated with an increased risk 
for insulin resistance and dyslipidemias (23), while being an 
independent risk factor for type II diabetes (24), hypertension 
(25), and all-cause mortality (26) (Figure 1B). By contrast, SAT 
is associated with improved or preserved insulin sensitivity, and 
mitigated risk of developing type II diabetes and other metabolic 
derangements (27, 28). Alternatively, it has been challenged 
whether VAT accumulation increases the risk for metabolic dys-
function (29, 30). Some have asserted that abdominal subcutane-
ous fat plays an independent role in developing an unfavorable 
metabolic profile (14, 31), dependent on how the subcutaneous 
fat is distributed among abdominal and gluteofemoral subcu-
taneous fat depots. In rats and mice, respectively, employing a 
lipectomy model, whereby the epididymal and retroperitoneal 
fat pads are surgically removed, improves insulin action, reduces 
tumorigenesis and improves longevity, independent of con-
founding factors (32–35). It deserves mentioning that surgically 
ablating the mesenteric fat pad in rodents cannot be sufficiently 
performed with current techniques due to the heavy innervation 
and vascularization of this tissue. Thus, given the general senti-
ment that rodent mesenteric fat is most analogous to the human 
intra-abdominal depot, it is tempting to speculate that the true 
importance of VAT gleaned from rodent lipectomy studies, has 
if anything, underestimated the “true” hazards associated with 
visceral adiposity. By contrast, some studies have shown that 
removal of omental fat in obese men and women in conjunc-
tion with gastric bypass surgery provided no added benefit to 
metabolic endpoints (36, 37). However, unlike rodent studies, 
where ~75% of visceral fat was removed, the omentum in obese 
subjects likely accounts for a small fraction (<10%) of total 
visceral adiposity, an amount that may have been insufficient to 
observe meaningful benefits.
Mechanistically, the benefits associated with SAT may be 
attributed to its ability to act as a metabolic “sink” to buffer against 
the daily influx of nutrients by providing long-term energy storage 
(38), thereby protecting against ectopic fat deposition and asso-
ciated lipotoxicity (3). Indeed, gluteofemoral fat in humans has 
been shown to have a protective role, such that it is independently 
associated with lower triglyceride levels (39), and higher concen-
tration of high-density lipoprotein cholesterol (40, 41). Studies 
have shown that femoral fat is associated with an elevated adipose 
tissue lipoprotein lipase activity (40, 42). Though the mechanisms 
responsible for depot differences in metabolic profiles still remain 
unclear, speculatively, gluteofemoral fat secretes more beneficial 
adipokines, as supported by studies in rodents (43), thereby 
producing less pro-inflammatory molecules compared to VAT 
(3). Indeed, it is widely believed that the deleterious effects of 
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elevated VAT can be attributed in part to an enhanced secretion of 
pro-inflammatory cytokines and the release of FFA, which have 
direct portal access to the liver (41, 44).
In humans, Jensen et al. (5) demonstrated that in moderately 
obese women, body fat distribution is predictive of FFA dysfunc-
tion, such that upper body obese women, but not lower body 
obese women, had an increased adipose tissue FFA release, when 
normalized for lean body mass. Furthermore, upper body obese 
women released almost twice the amount of calories as lower 
body obese individuals. Speculatively, the differences in meta-
bolic function between these two states could also be attributed 
to adipocyte hypertrophy, which occurred in the upper body 
obese women during weight gain, as opposed to hyperplasia, 
which was observed in the lower body obese. Therefore, the 
adipocytes in the lower body obese were still of normal size 
with more restrained lipolysis, while the upper body adipocytes 
were enlarged with increased lipolysis. Importantly, many of the 
hazardous metabolic sequelae secreted from adipose tissue have 
been linked to enlarged hypoxic adipocytes (45, 46).
In rodents, surgically transplanting subcutaneous fat has dem-
onstrated either no deleterious effect or even proven beneficial to 
the recipient in some reports. By contrast, when subcutaneous 
fat was removed from mice, there was a significant increase in 
serum triglycerides and basal insulinemic index, which implies a 
quantitative role for subcutaneous fat acting as a metabolic “sink” 
(9, 47). Likewise, subcutaneous, but not visceral fat transplants, 
improved glucose metabolism in mice, particularly when they 
were placed in the viscera (43). It should be noted that large-
volume liposuction (~10 kg) of subcutaneous fat in humans nei-
ther improved nor harmed the metabolic (48) or cardiovascular 
risk profile (49). Importantly, a redistribution of fat stores is a 
hallmark of aging and is characterized by a depletion of subcuta-
neous fat stores in older rodents and humans, which contributes 
to a simultaneous expansion of visceral and ectopic fat stores in 
sites such as liver, pancreas, bone, and skeletal muscle (50). Thus, 
taken together, these observations suggest that subcutaneous fat 
may be beneficial in both rodents and humans, not only via its 
own secretions but also by mitigating the accretion of fat in other 
more harmful sites with obesity and aging, including visceral and 
ectopic stores.
Beyond the contribution of VAT per se, an emerging associa-
tion with specific sites of SAT have been linked with increased 
metabolic dysfunction in humans (30, 31, 51). As previously 
stated, subcutaneous fat is divided into two layers: superficial and 
deep (14, 15). Johnson et al. (15) investigated abdominal adipose 
tissue in obese women and determined that the area of DSAT was 
highly correlated with the area of VAT. Similarly, Kelley et al. (52) 
examined both lean and obese men and women, and found that 
DSAT and VAT were both strongly correlated with glucose, insu-
lin, HDL, and triglycerides, whereas SSAT had a much weaker 
association, and more closely mirrored gluteofemoral SAT. Smith 
et al. (14) found that DSAT was correlated with VAT, as well as 
with fasting insulin levels. Because DSAT follows a pattern more 
associated with VAT, and SSAT parallels gluteofemoral adiposity, 
the location of adipose tissue sampling, either above or below the 
fascia, needs to be taken into account as these conclusions sup-
port the hypothesis that SAT is heterogeneous, having different 
physiological effects depending on depot location. Rodents do 
not harbor fat pads that are clearly analogous to the DSAT layer, 
though it is possible that the so-called peri-visceral fat pads 
(gonadal, retroperitoneal), which tracks with mesenteric fat mass, 
may be relevant candidates to explore in future studies.
SeXUAL DiMORPHiSM iN ADiPOSe 
TiSSUe ReGULATiON AND FUNCTiON
It has been recognized that the development of adipose 
depots during positive energy balance differs according to sex. 
Independent of BMI, women typically carry 10% more body 
fat than their male counterparts (53, 54). Demerath et  al. (55) 
found that women typically have greater total body fat than men. 
Additionally, compared to men, women have greater SAT in the 
abdominal and gluteofemoral depots, independent of total body 
fat (55, 56).
Not only does SAT area and volume differ between sexes, but 
also the spatial distribution of SAT. Regardless of race, women 
tend to harbor greater SAT in the lower abdomen, and in general, 
have lower visceral content than men (55, 56). One explanation 
for the increase in subcutaneous adiposity in women may be 
attributed to preferential increases in SSAT rather than in DSAT. 
The area of the deep subcutaneous depot is inversely associated 
with fasting insulin levels (14) and, in general, women have lower 
visceral content than men (55, 56). This may partially contribute 
to why, on average, pre-menopausal women tend to have healthier 
metabolic risk profiles compared to men, irrespective of total fat 
content. Nevertheless, it is acknowledged that additional factors, 
such as reproductive hormones and differential racial responses, 
influence both fat quantity and distribution.
As stated previously, women have more SAT than men, while 
men have more VAT than women (57). Thus, it is not surprising 
that leptin is a better correlate for body fat in females (58), as SAT 
secretes more leptin than VAT. By contrast, insulin is a better cor-
relate for body fat in males (58), as insulin is more related to VAT 
than SAT (57). Because of the aforementioned sex differences in 
fat deposition, and their relation with various co-morbidities, it 
is important to consider whether these sex differences similarly 
exist in rodents, in order to promote their pre-clinical value as a 
guide for relevant translational research.
To date, the sexual dimorphism seen in humans is less docu-
mented in rodents (59, 60), although some inferences have been 
made. For example, similar to humans, female rats have higher 
plasma leptin levels compared to male rats (58), independent of 
body composition differences (61). Consistent with these obser-
vations is the brain sensitivity to these hormones, with male rats 
demonstrating greater central sensitivity to insulin, while females 
were more responsive to leptin (58).
Similar to humans, female rodents harbor greater fat mass 
compared to their male counterparts, but remain more insulin 
sensitive. Macotela et al. (60) showed that isolated adipocytes from 
subcutaneous fat of female mice were more insulin sensitive than 
male-derived subcutaneous fat. However, when further examin-
ing inter-depot insulin sensitivity in female mice, the periovarian 
fat pad proved to be more insulin sensitive than the inguinal fat 
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pad (60), a finding that is at odds with data from humans, where 
the gluteofemoral depot has proven to be the most sensitive SAT in 
females (62), and is also more insulin sensitive than the VAT (63).
An additional similarity between the species is spatial pat-
terning of the adipose tissue with changes in sex hormones. 
Postmenopausal women preferentially redistribute adipose tissue 
from the gluteofemoral region to the abdomen, which mirrors 
the accrual of visceral fat observed with aging in men. Likewise, 
Grove et al. (59) demonstrated that ovariectomized female mice 
demonstrated a significant increase in adiposity similar to adipose 
tissue accumulation patterning in males, including an increase in 
total and visceral fat. However, whether ovariectomizing young 
rodents truly recapitulates female menopause in humans, which 
occurs during late-middle age, is debatable, and thus should be 
interpreted with caution.
Though similarities exist, other notable differences in regards 
to sex differences have been observed between species. One 
example is the fat pad composition and location associated with 
sex hormones (i.e., estrogen and testosterone) in rodents. For 
instance, the inguinal white adipose tissue (WAT) of female mice 
contains mammary glands, while the gonadal fat pad is situated 
near the reproductive tissue. This is not the case in humans, 
where the mammary glands are located in the breast tissue. 
Furthermore, unlike their male counterparts, several strains of 
female mice are relatively resistant to obesity on a high-fat diet 
(64, 65), but this protection can be removed by ovariectomizing 
the animal (66, 67). Thus, while fat patterning in adult females 
seems to be influenced strongly by reproductive hormones, overt 
protection against weight gain and obesity does not seem to be a 
shared characteristic between female rodents and humans.
weiGHT LOSS
Regardless of sex, obese individuals undergoing weight loss 
preferentially decrease their VAT compared to SAT (68). Indeed, 
significant volumes of VAT are lost when subjected to caloric 
restriction (CR) and/or a physical activity intervention (69). 
Additionally, when SAT is mobilized in obese individuals, there 
is a greater increase in lipid mobilization in the abdominal region 
compared to the gluteofemoral region (8, 70, 71), which shows 
only a minimal change in mobilization (71). This preferential 
reduction in abdominal adipose tissue is consistent with the 
observation that adipocytes from the omental and mesenteric 
depots are more lipolytically active, when compared to adipocytes 
found in the gluteofemoral region (72–74).
When male rodents are subjected to CR or leptin treatment, 
an examination of weight loss effects on adipose tissue volume 
and spatial distribution (8, 75) reveals a preferential reduction in 
VAT compared with other adipose depots (76), while some have 
shown that male rodents lose both VAT and SAT (77). Similarly, 
female mice tend to conserve their SAT by preferentially reducing 
their visceral fat stores (77). This would be somewhat analogous 
to human studies, where both men and women reduce their vis-
ceral fat stores, with a greater extent occurring in men compared 
to women (78, 79).
Furthermore, as the majority of people who undergo diet-
induced weight reduction regain the lost weight over time, it 
is important to determine if the same phenomenon is seen in 
rodents. Male mice exposed to ad  libitum feeding following 
CR-induced weight loss demonstrated gains in both visceral 
and subcutaneous fat stores. However, female mice did not 
follow this same pattern, and were less capable of regaining 
visceral fat after weight loss (77). Speculatively, this may be 
attributed to reproductive hormones or to sex differences in 
leptin concentrations. Circulating leptin decreases with CR, 
but increases with ad libitum feeding in male mice, presumably 
due to increases in adiposity and food intake. In female mice, 
leptin patterns appear to differ from males. For example, while 
leptin concentrations are similarly reduced with CR in females 
(6, 80), they remain reduced after refeeding, as compared to 
ad  libitum-fed controls (80), while others have shown leptin 
levels unchanged in response to either CR or refeeding (77). 
Irrespective of weight loss and body composition, women have 
higher levels of leptin compared to men (55), but both obese 
men and women who undergo CR, proportionately decrease 
leptin levels with the reduction of total fat, as well as visceral 
and subcutaneous fat (68). Interestingly, in children, when 
adjusting for body composition and fat deposition, sex has no 
independent effect on leptin concentrations (81). In addition, 
adults attempting to lose weight tend to engage in multiple 
episodes of weight loss and regain (e.g., weight cycling); thus, 
it is important to examine the effects of this flux in body 
composition and fat deposition on leptin concentration in 
adult humans. Interestingly, the association between leptin 
concentration and weight cycling holds true for females, but 
not for males (82). Importantly, the fact that both female and 
male mice show an increase in fat deposition after CR in a 
manner reminiscent of humans during weight regain suggests 
that rodents may be an informative model toward elucidating 
many sexually dimorphic traits related to fluctuations in energy 
balance and storage (83).
LiPOLYSiS
Lipolysis, which is the active breakdown of triglycerides to 
FFAs and glycerol, has been widely studied in both rodents and 
humans. Many striking similarities in the regulation of lipolysis 
exist among species, including stimulation by catecholamines, 
growth hormone, testosterone, and cortisol (corticosterone 
in rodents), as well as inhibition by insulin. Lipolysis can be 
stimulated in rodents and humans under similar physiological 
contexts, including fasting, exercise, and stress. While, activation 
of the sympathetic nervous system and subsequent release of 
epinephrine, norepinephrine, and cortisol represents a major 
driver of lipolysis in humans (84) and rodents (85), important 
differences between rodents and humans exist in how some of 
these pathways drive lipolysis.
Catecholamine-driven lipolysis, which occurs by activating 
three different β-adrenergic receptor (AR) subtypes, β1, β2, and 
β3, provides one important example. ARs are coupled to a Gα 
subunit, and catecholamine induced activation leads to a cascade 
of events culminating in lipolysis, including increased cAMP by 
adenylyl cyclase, activation of protein kinase A, and activation of 
hormone-sensitive lipase, enabling its translocation to the lipid 
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droplets to catalyze the hydrolysis of triglycerides (86). Both 
β1-AR and β2-AR are ubiquitously expressed in rodents and 
humans, whereas β3-AR expression is more tissue and species 
specific, with expression confined to WAT in rodents, while only 
being marginally expressed in human adipocytes (87). Indeed β3-
adrenergic agonists induce a lipolytic response in rodents (88), 
but fail to significantly stimulate lipolysis in human adipocytes, 
in vitro (89) and in vivo (90).
In humans, α2-ARs, as compared to β-ARs, are highly 
expressed in SAT, and have a greater affinity for catechola-
mines (91), while this G-coupled protein receptor is absent in 
rodent adipocytes. In humans, α2-AR acts to inhibit lipolysis 
by decreasing cAMP levels. Indeed catecholamine activation 
of α2-ARs in non-obese humans has been shown to partially 
down regulate lipolysis in SAT (92). Further support of α2-AR 
regulating lipolysis was gleamed from rodent studies whereby 
the human α2-AR was expressed in transgenic mice on a β3-
AR knockout background. Specifically, these animals exhibited 
a blunted catecholamine-stimulated lipolysis response and an 
obese phenotype (93). Therefore, it appears a balance between 
α2-AR and β-AR is necessary for lipolysis regulation, at least in 
humans (87).
Historically, the major circulating factors regulating lipolysis in 
human WAT have been appreciated to be catecholamines, growth 
hormone, cortisol, testosterone, and ghrelin (94). However, more 
recently, it has been shown that natriuretic peptide [extensively 
reviewed in Ref. (95)] induces lipolysis in  vitro and in  vivo 
(96), independently of the catecholamine-AR pathway (97), 
via a cGMP-dependent mechanism (96). However, natriuretic 
peptide lipolysis is apparently primate specific. Sengenès and 
colleagues showed that only primate adipocytes (i.e., humans 
and macaques) showed natriuretic peptide-induced lipolysis, 
while this effect was absent in rats, mice, hamsters, and other 
non-rodent mammals.
In summary, important similarities exist in the biology 
of rodent and human adipose tissue lipolysis, but as we have 
discussed, many important distinctions have been identified 
that warrant consideration when utilizing rodent models. 
Such differences are apparent in the species specificity of β-AR 
expression on adipocytes, and the distinct roles of α2-ARs and 
natriuretic peptide in regulating human, but not rodent adipose 
tissue lipolysis. Likewise, some lipolytic agents active in rodent 
adipocytes fail to have similar effects in human adipocytes (91). 
For example, adrenocorticotropic hormone (ACTH) induces 
lipolysis in mouse (98) and rat adipocytes (99, 100), respectively, 
while alpha-melanocyte-stimulating hormone (αMSH) was also 
shown to modulate murine adipocytes (101). However, neither 
ACTH or αMSH – induce lipolytic activity in human adipocytes 
(98, 102). Therefore, it is important to balance and account for 
these important differences against commonalities in the biology 
of adipose tissue lipolysis among species.
FAT PADS AND FAT DePOTS AS AN 
eNDOCRiNe ORGAN
Adipose tissue, which is made up of numerous cell types, including 
pre-adipocytes, adipocytes, T cells, B cells, and stromovascular 
cells, is now appreciated as an active endocrine organ, capable 
of secreting numerous humoral factors. Indeed, systemic levels 
of adipokines, including leptin, interleukin (IL) 1-β, IL-6, and 
tumor necrosis factor-α (TNF-α), are actively secreted and levels 
rise with increasing fat mass. On the other hand, adiponectin has 
been linked to many beneficial effects, but levels correlate nega-
tively with increasing adiposity (103). Because these adipokines 
have pleiotropic actions, including extensive metabolic effects, it 
is important to determine if secretion is similar among humans 
and rodents with respect to depot location.
As mentioned previously, leptin is preferentially secreted in 
humans from peripheral subcutaneous depots at a higher rate 
than from VAT (103, 104), indicating that subcutaneous fat is a 
chief source of leptin production. Likewise, leptin expression was 
shown to be greater in rat inguinal as compared to epididymal fat 
pads (105). IL-6 is another important cytokine that is produced 
in significant amounts from adipose tissue. Mohamed-Ali et al. 
(106) showed that SAT is capable of producing IL-6, while Fontana 
et al. (103) demonstrated that IL-6 secretion is greater from VAT 
than from SAT in obese individuals (103). Furthermore, IL-6 
levels are elevated in middle-aged men with visceral adiposity, 
as compared to lean men, and adjusting for visceral fat accounts 
for the rise in IL-6 with visceral obesity (107). Other fat-derived 
factors, such as TNF-α, show similar secretion patterns in VAT 
and SAT in humans (103), but adipose-derived TNF-α has been 
suspected to act in more an autocrine/paracrine rather than 
endocrine manner.
The data are less clear for adiponectin secretion from different 
human depots. Phillips et al. (108) showed that SAT secretes more 
adiponectin compared to VAT, while obese individuals demon-
strate impaired total adiponectin secretion from SAT, but not from 
VAT depots (109). Meanwhile, some have reported no significant 
difference in total adiponectin secretion between subcutaneous 
and visceral adipocytes (103, 109), while others have shown that 
cultured visceral adipocytes secrete more adiponectin compared 
to subcutaneous adipocytes (104). Likewise, adiponectin expres-
sion from rat epididymal fat pads was significantly greater than 
that from inguinal fat (105).
In regard to evidence from rodents, a microarray study in 
isolated epididymal and inguinal fat pads from rats first showed 
marked differences in these tissues, including increased expres-
sion of resistin, angiotensinogen, adiponectin, and PPARγ in 
epididymal tissue, while inguinal fat demonstrated greater 
expression of PAI-1 and leptin. Studies have also assessed the 
effect of surgically removing the epididymal and perinephric 
fat pads on circulating levels of adipokines. Pitombo et al. (110) 
showed selective ablation of these fat pads restored insulin action 
and normalized TNF-α, IL-6, and adiponectin levels. By contrast, 
surgical removal of visceral fat pads in a male and female mouse 
model of intestinal cancer fed a high-fat diet led to sexually 
dimorphic responses. In males, lipectomy reduced adiponectin 
levels, but did not alter other adipokines, presumably due in part 
to a compensatory expansion of the mesenteric fat pad (6). By 
contrast, females had higher circulating levels of adiponectin 
than males, and while lipectomy reduced circulating levels, they 
remained at higher concentrations than observed in control 
males. Furthermore, no compensatory change was observed in 
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mesenteric fat pad mass in females, but leptin levels were sig-
nificantly elevated, suggesting the expansion of subcutaneous fat 
stores. Unfortunately, the literature does not provide additional 
information regarding adipokine secretion in rodent models in 
relation to specific fat pads.
Finally, almost all studies evaluating circulating levels of adi-
pokines are conducted according to clinical trial protocols, which 
often require the patient to fast overnight prior to blood sampling. 
However, measuring levels and expression patterns under basal 
conditions may be misleading as it is now recognized that nutri-
ents can provoke the expression and production of adipokines 
from adipose tissue. Indeed, most humans (and rodents) spend 
the majority of their day in the postprandial state, and as a result, 
the expression and secretion of adipokines from fat depots and 
fat pads may be severely underestimated. Einstein et  al. (111) 
first showed that when rats were exposed to hyperglycemia and 
hyperinsulinemia, expression of several peptides in fat, includ-
ing resistin, adiponectin, leptin, PAI-1, and angiotensinogen, 
was markedly increased by 2- to 10-fold in epididymal fat pads, 
but less dramatically in subcutaneous fat. Similar patterns were 
also observed when animals were challenged with glucosamine 
(112) or FFA (113), and some of these responses were further 
exaggerated in aging rats. Similarly, Kishore et al. (114) showed 
in humans that adipose-derived factors from subcutaneous fat 
potentiate PAI-1 secretion from macrophages in response to 
FFAs. Furthermore, this response is similarly exaggerated in 
macrophages obtained from middle-aged versus younger-adult 
subjects (115). Mechanistically, these effects have been linked to 
increased flux through the hexosamine biosynthetic pathway as 
well as TLR4 receptors. It is also important to keep in mind that 
these comparisons, while informative, are made on a per mil-
ligram tissue or mRNA basis and do not necessarily account for 
the absolute fat pad size and, hence, overall contribution to whole 
body levels in vivo. Thus, given the inherent size of the visceral 
pads in relation to the inguinal tissue in rodents, the contribution 
of visceral fat to these secreted factors, particularly in response to 
nutrients, could be quite large. However, the relative contribu-
tion of visceral fat-derived cytokine release to the overall nutrient 
response in vivo, has not been carefully evaluated. Nevertheless, 
based on the current literature, it appears that adipokine secretion 
patterns in humans are predominantly similar to what has been 
shown in rodent studies.
HORMONAL AND GeNeTiC FACTORS 
GOveRNiNG FAT PAD DeveLOPMeNT 
AND eXPANSiON
As mentioned, many uncertainties remain regarding the mecha-
nistic underpinnings responsible for the physiological differences 
among depots. During weight gain, different depots enlarge via 
hyperplasia, hypertrophy, or both (116), with new adipocytes 
generating more readily in some depots compared to others. 
The inter-depot physiological enlargement differences are likely 
influenced by both extrinsic and intrinsic factors.
Genetic factors have also been shown to influence the distri-
bution of adipose tissue (117–119). The BMI of an individual is 
highly heritable and can possibly account for as much as 70% of 
the variance (117). However, C57BL/6 mice, which are inbred, 
and theoretically should be identical genetically, demonstrate 
marked variance in body mass, adiposity, and feeding behavior, 
even when the mice are fed the same diet type (120), perhaps due 
to epigenetic effects (121).
Although genetic factors have been implicated in fat pad 
growth and expansion, the genetic underpinnings controlling 
these processes are not as well understood. A few investigations 
have been conducted to elucidate the gene(s) that moderate the 
distribution of adiposity. Recently, Loh et al. (122) showed LRP5 
is involved in fat distribution. Individuals with gain-of-function 
LRP5 mutations are characterized with increased lower-body fat 
accumulation, compared to age-, sex-, and BMI-matched con-
trols. However, more attention has focused recently on adipocytes 
from different depots, which have shown differential gene expres-
sion (105, 119, 123) and proliferative capacity (124, 125). When 
examining the transcripts that differed around a quarter were 
found to be developmental regulators (126–128), in particular 
the homeobox (HOX) superfamily of genes. Investigations have 
now started to actively examine differential HOX gene expression 
between depots in order to assist in determining the underpin-
nings of abdominal versus gluteofemoral adiposity (10, 123, 128, 
129). A summary of the HOX gene network in rodent and human 
adipose tissue is provided in Table 1.
In addition to genetic contributors, structural and hormonal 
regulators have been shown to influence fat distribution. Scherer 
and colleagues (132) examined extracellular matrix components 
of adipose tissue, specifically collagen VI, under different meta-
bolic conditions. In the absence of collagen VI, adipocytes were 
capable of unrestricted expansion, resulting in further lipid storage 
and a reduction in ectopic fat deposition (132). Interestingly, even 
with greater fat expansion, under both high-fat diet conditions 
and on an ob/ob background, collagen VI knockouts compared to 
controls had improved metabolic phenotypes. To determine if a 
similar relationship between increased collagen VI and metabolic 
stress existed in humans, Scherer and colleagues investigated 
an Asian Indian population due to their propensity to be more 
insulin resistant compared to BMI-matched Caucasians (133). 
Collagen VI alpha 3 (col6a3), a major adipocyte-derived secre-
tory protein with increased expression during states of metabolic 
stress in ob/ob and db/db mice, was compared between Asian 
Indian and control matched Caucasians. Similar to the rodent 
models, col6a3 expression was significantly greater in abdominal 
and gluteal subcutaneous adipose depots in the investigated 
Asian Indians (132). Collectively, there is evidence that in terms 
of collagen VI, there may be similar adipocyte physiology in both 
rodents and humans that may inhibit expansion of adipose tissue.
Similar to the collagen VI model, overexpression of adiponec-
tin in ob/ob mice lead to an increase in adipocyte cell number 
and, thus, increased adipose tissue mass, specifically SAT (134). 
However, even with the observed hypertrophy, the unrestricted 
expansion of adipose tissue associated with elevated adiponectin 
levels resulted in a major improvement in the overall metabolic 
phenotype, even in an obese state (134). The authors speculated 
that the improvement in metabolic parameters was partially 
attributed to increased PPARγ activity in adipocytes, leading 
TABLe 1 | expression patterns of the HOX gene network in human fat 
depots and mouse fat pads.
Human Mouse















































Data were obtained from Cantille et al. (130)a, Vohl et al. (123)b, Karastergiou et al. 
(128)c, Gesta et al. (10)d, Tchkonia et al. (126)e, and Brune et al. (131)f.
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to a redistribution of lipids from ectopic sites to SAT. Likewise, 
increased adiponectin levels may also play a role in human obesity. 
Bouatia-Naji and colleagues (135) investigated common single 
nucleotide polymorphisms (SNPs) in the ACDC adiponectin 
encoding gene in French Caucasians and concluded that hyper-
adiponectinemia may be associated with severe obesity.
Adiponectin levels are also increased in growth hormone 
receptor knockout (GHRKO) mice (136), likely because adi-
ponectin is negatively regulated by GH (137). Similar to the above 
transgenic models, GHRKO mice are characterized by greater 
relative amounts of body fat in both males and females, with a 
disproportionate amount of fat deposition in SAT (138). In spite 
of harboring greater amounts of adipose tissue, GHRKO mice 
are metabolically healthy, an effect attributed to their increased 
adiponectin levels (139). Interestingly, Laron dwarfism, which 
is a human syndrome characterized by defective GH signaling, 
is characterized by obesity, in spite of a small stature, but these 
individuals are protected against type 2 diabetes (140) and have 
elevated adiponectin levels (141). Thus, humans and rodents 
may have a similar response to reduced GH/IGF-1 signaling and 
associated increased levels of adiponectin on fat accretion and 
patterning as well as glucose metabolism.
Glucocorticoids also influence adipose tissue differentia-
tion, function, and distribution. High levels of glucocorticoids 
partially contribute to visceral obesity in conjunction with 
diabetes, hyperlipidemia, and hypertension (142, 143). One 
mechanism for the production of glucocorticoids is through the 
enzyme 11-β-hydroxysteroid dehydrogenase type 1 (11β HSD-
1). Interestingly, Masuzaki and colleagues (144) created a mouse 
model overexpressing 11β HSD-1 selectively in adipose tissue 
that reflected 11β HSD-1 levels observed in adipose tissue from 
obese humans, who are reported to have increased 11β HSD-1 
activity. They observed that a modest increase in 11β HSD-1 
activity was sufficient to induce hyperphagia and increased VAT 
accumulation. Furthermore, the increased VAT accumulation 
was attributed to significantly greater glucocorticoid receptor 
alpha isoform expression in mesenteric compared to SAT. In 
addition, increased corticosterone release into the portal vein 
of rodents may contribute to the observed rise in portal FFA 
levels, which parallels the increase in FFA levels in humans char-
acterized by high circulating cortisol and metabolic syndrome 
(145–148). Collectively, it appears that structural and hormonal 
factors associated with increases in adipose tissue are largely 
similar in both humans and rodents. Therefore, rodents appear 
to be a viable model of human adipose tissue regulation by many 
common hormonal factors.
CONCLUSiON
It is understood that not all obese individuals are at the same 
risk for developing metabolic perturbations and that body fat 
distribution is an important determinant of obesity-related 
complications. Individuals with increased upper-body adiposity 
are disproportionately burdened by obesity-related diseases, 
compared to lower-body obese individuals. Thus, it is paramount 
that studies continue to elucidate the pathways linking various 
adipose pads and depots in relation to health and disease, as 
well as the mechanistic underpinnings dictating how body fat is 
distributed in order to answer fundamental questions. Rodents 
are commonly used to model features of human metabolism 
and obesity, yet it is unclear to what extent rodent fat pads are a 
suitable model of human fat depots. Here, we have highlighted 
examples of both shared and divergent traits among rodent fat 
pads and human fat depots. Given some of the stark differences 
in adipose tissue location and function among species, we urge 
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careful consideration in experimental design and interpretation 
when attempting to draw definitive parallels between rodent fat 
pads and human fat depots.
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